Kailera Therapeutics, Inc. (KLRA) Stock Research

Over a week ago

Kailera Therapeutics announces positive Phase 3 data for weight loss drug

KLRA

Jul 7, 9:33 AM

Kailera appoints Kathleen Tregoning as chief corporate affairs officer

KLRA

Jun 29, 7:44 AM

Kailera Therapeutics initiated with bullish view at Evercore ISI, here's why

KLRA

May 12, 8:16 AM

Kailera Therapeutics initiated with bullish view at Leerink, here's why

May 12, 7:40 AM

Kailera Therapeutics initiated with bullish view at TD Cowen, here's why

KLRA

May 12, 5:33 AM

Kailera Therapeutics initiated with bullish view at William Blair, here's why

KLRA

May 12, 5:14 AM

Kailera Therapeutics initiated with bullish view at JPMorgan, here's why

KLRA

May 12, 5:05 AM

Kailera Therapeutics initiated with bullish view at Jefferies, here's why

KLRA

May 12, 5:00 AM

Opening Day: HawkEye 360 jumps in debut after high‑end pricing

+12

May 11, 11:23 AM

PMV Pharmaceuticals chair Rich Heyman to depart, Laurie Stelzer to succeed

Apr 22, 8:14 AM

Opening Day: Drone maker AEVEX pops on debut

+10

Apr 20, 11:20 AM

Kailera Therapeutics opens at $26, IPO priced at $16 per share

KLRA

Apr 17, 1:26 PM

Kailera Therapeutics indicated to open at $21, IPO priced at $16

KLRA

Apr 17, 11:42 AM

Kailera Therapeutics indicated to open at $24, IPO priced at $16

KLRA

Apr 17, 10:39 AM

Kailera Therapeutics 39.06M share IPO priced at $16.00

KLRA

Apr 16, 8:02 PM

Kailera Therapeutics 33.333M share IPO price range $14.00-$16.00

KLRA

Apr 13, 10:03 AM

No more stories